Based on results from these large trials and other smaller randomized trials, the Technology Assessment of Aromatase Inhibitors Status Report 2004 from the American Society of Clinical Oncology (asco) recommends that, to lower the risk of recurrence, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include ais. This evidence concerns the gene CYP19A1 and breast carcinoma.